Long‐term outcomes of a phase II randomized controlled trial comparing intensity‐modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma. Issue 1 (15th February 2016)

• Record Type: Journal Article
• Authors: Guan, Ying; Liu, Shuai; Wang, Han‐Yu; Guo, Ying; Xiao, Wei‐Wei; Chen, Chun‐Yan; Zhao, Chong; Lu, Tai‐Xiang; Han, Fei
• Is Part Of: Cancer communications. Volume 35:Issue 1(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-02-15
• Subjects: Recurrence -- Nasopharyngeal carcinoma -- Intensity‐modulated radiation therapy -- Concomitant chemoradiotherapy -- Cisplatin; Cancer -- Periodicals; Neoplasms; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 616.994005
• DOI: 10.1186/s40880-016-0081-7
• Languages: English
• ISSNs: 2523-3548

Abstract

Abstract: Background: Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity‐modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC. Methods: Between April 2002 and January 2008, 69 patients diagnosed with non‐metastatic locally recurrent NPC were randomly assigned to either concomitant chemoradiotherapy group ( n = 34) or radiotherapy alone group ( n = 35). All patients received intensity‐modulated radiotherapy. The radiotherapy dose for both groups was 60 Gy in 27 fractions for 37 days (range 23–53 days). The concomitant chemotherapy schedule was cisplatin 30 mg/m 2 by intravenous infusion weekly during radiotherapy. Results: The median follow‐up period of all patients was 35 months (range 2–112 months). Between concomitant chemoradiotherapy and radiotherapy groups, there was only significant difference in the 3‐year and 5‐year overall survival (OS) rates (68.7% vs. 42.2%, P = 0.016 and 41.8% vs. 27.5%, P = 0.049, respectively). Subgroup analysis showed that concomitant chemoradiotherapy significantly improved the 5‐year OS rate especially for patients in stage rT3–4 (33.0% vs. 13.2%, P = 0.009), stages III–IV (34.3% vs. 13.2%, P = 0.006), recurrence interval >30 months (49.0% vs. 20.6%, P = 0.017), and tumor volume >26 cm 3 (37.6% vs. 0%, P = 0.006). Conclusion: Compared with radiotherapy alone, concomitant chemoradiotherapy can improve OS of the patients with locally recurrent NPC, especially those with advanced T category (rT3–4) and stage (III–IV) diseases, recurrence intervals >30 months, and tumor volume >26 cm 3 .